Bio Path Holdings Inc (NASDAQ: BPTH) is a clinical-stage oncology biopharmaceutical company that develops RNA-interference cancer therapeutics. The company does not generate product revenue; it funds operations through equity financings and has no commercial products as of the 10-K filed 2025-03-27. The filing excerpts provided do not contain sufficient detail to characterize BPTH's pipeline assets, clinical stage, competitive position, leadership, founding year, or capital structure with the specificity required for a fully sourced description. Based solely on the available filing excerpts, BPTH is a pre-revenue biopharmaceutical company whose common stock carries a par value of $0.001 per share and is registered under Section 12(g) of the Securities Exchange Act.

Source: SEC 10-K, filed 2025-03-27

Industry: Pharmaceutical Preparations Peers: Serina Therapeutics Inc REGENERX BIOPHARMACEUTICALS INC Onconetix Inc Cellectar Biosciences Inc Forte Biosciences Inc Inhibikase Therapeutics Inc Vincerx Pharma, Inc. Oncotelic Therapeutics Inc Oncorus, Inc.